[go: up one dir, main page]

US20060188559A1 - Topical cosmetic compositions comprising alpha arbutin - Google Patents

Topical cosmetic compositions comprising alpha arbutin Download PDF

Info

Publication number
US20060188559A1
US20060188559A1 US11/060,348 US6034805A US2006188559A1 US 20060188559 A1 US20060188559 A1 US 20060188559A1 US 6034805 A US6034805 A US 6034805A US 2006188559 A1 US2006188559 A1 US 2006188559A1
Authority
US
United States
Prior art keywords
alpha arbutin
arbutin
alpha
composition
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/060,348
Inventor
Arnold Neis
Robert Neis
Jerry Whittemore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Browne E T Drug Co Inc
Original Assignee
Browne E T Drug Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Browne E T Drug Co Inc filed Critical Browne E T Drug Co Inc
Priority to US11/060,348 priority Critical patent/US20060188559A1/en
Assigned to E.T. BROWN DRUG CO., INC. reassignment E.T. BROWN DRUG CO., INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WHITTEMORE, JERRY, NEIS, ARNOLD, NEIS, ROBERT
Assigned to E.T. Browne Drug Co., Inc. reassignment E.T. Browne Drug Co., Inc. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 016670 FRAME 0334. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME FROM E.T. BROWN DRUG CO., INC. TO E.T. BROWNE DRUG CO., INC.. Assignors: WHITTEMORE, JERRY, NEIS, ARNOLD, NEIS, ROBERT
Publication of US20060188559A1 publication Critical patent/US20060188559A1/en
Priority to US11/745,632 priority patent/US7431949B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the invention relates to topical cosmetic compositions, in particular, human skin lightening compositions, comprising admixtures of alpha arbutin and bearberry extract used for topical application.
  • the present invention is a novel topically applied dermocosmetic composition comprising certain admixtures of the glucoside alpha arbutin and the botanical extract bearberry to be used in skin lightening.
  • Melanocytes are located deep in the stratum granulosum, produce melanin, and through an unknown mechanism the melanin rises through about 100 cell layers to the surface where they exist as unsightly dark spots.
  • Tyrosinase is the enzyme which catalyzes the amino acid tyrosine into dopa (dihydroxyphenylamine), as well as the change from dopa into dopaquinone.
  • Skin lightening products are designed to inhibit the action of tyrosinase.
  • Hydroquinone is the most common inhibitor of the enzyme tyrosinase. Hydroquinone is OTC Monographed (United States Food and Drug Administration 21 CFR) as a Category I skin lightener/skin bleacher/skin whitener in the concentration limits of 1.5-2.0% by weight. Used in this concentration, no clinical trials and no pre-market clearance are necessary in the USA marketplace. Used in higher concentrations than 2% by weight, hydroquinone compositions legally require a prescription in the USA marketplace. Production of hydroquinone preparations over 2% by weight requires an approved ANDA (Approved New Drug Application-21 CFR 394). However, hydroquinone is an irritant to some individuals, particularly those with light skin types, and may be cytotoxic to melanocytes. It is not legally marketed in Japan, the Union of South Africa and several other countries at present, and several other countries are considering denying legal marketing clearance because of concern about long term toxicity.
  • Alpha arbutin avoids the direct toxicity of hydroquinone and the indirect toxicity of beta arbutin which easily hydrolyses to hydroquinone.
  • Alpha arbutin acts more slowly than hydroquinone, taking a slightly longer time to meet the customer's skin lightening objectives when used alone.
  • This invention involves the use of alpha arbutin and bearberry extract in combination, This combination is synergistic in skin whitening effectiveness, as the bearberry extract serves to potentiate the alpha arbutin.
  • the alpha-glucosidic bond has a higher stability than the beta gluosidic bond, giving greater stability and greater effectiveness than beta arbutin.
  • This invention teaches that the use of polyolprepolymer-2, when admixed with the serum comprised of alpha arbutin and octyl stearate, can be administered into the human skin using a liposome advanced delivery mechanism.
  • Liposomes can easily be formed by those familiar in the art of liposome manufacture, using either preformed empty liposomes (Brookosomes MT) or by using ultra high pressure (20,000-40,000 PSI) in the usual microfluidizer.
  • a serum comprised of alpha arbutin 0.01-6.0% w/w (more preferably 1-4% w/w) plus bearberry extract 0.01% w/w (most preferably 1-3% w/w) is admixed with polyolprepolymer-2 0.5-10% w/w (most preferably 1-3% w/w), and this combination is further prepared into a liposome form with the use of lecithin, water and ultra high pressure microfludizer.
  • the liposome formation is well known to those familiar in the use of the ultra high PSI providing microfluidizer.
  • This invention additionally teaches the serum-liposome admixture being further admixed into a gel or cream carrier as an advanced delivery system used in cosmetic, esthetician, spa and dermatology office settings.
  • this stabilized alpha arbutin-polyolprepolymer 2-liposome concentrate which has been diluted into a cosmetic carrier, is potentiated with the admixture of the proven botanical extract, bearberry extract.
  • additional nutrients including Vitamins A, B, C, E and Panthenol may be included in the liposome addition process.
  • the most preferable embodiment composition is as follows: Part Ingredient INCI Percentage by weight A Aqua (water) qs 100% A Methylparaben 0.23 A Glycerin 4 A EDTA disodium 0.12 B Cetearyl alcohol, ceteareth 20 9 B Propylparaben 0.12 B Cetyl palmitate 2 B Dimethicone 50 1 B Steareth-20 1 C Alpha arbutin 3 C Octyl stearate 7 C Polyolprepolymer-2 2 D Lecithin, Water 1 (Brookosomes MT) Lecithin, Vitamins A, C & E 1 E Bearberry Extract 1 (Gatulin-Gattefosse)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention is a topical tyrosinase inhibiting combination using alpha arbutin and bearberry extract, in synergism, for the purpose of skin lightening. The active admixture is a dermatological serum comprised of alpha arbutin, octyl stearate and polyolprepolymer-2, introduced onto the human skin in liposome form for ultra-deep penetration.

Description

    REFERENCES CITED [REFERENCED BY] U.S. Patent Documents
  • 6,695,260 May, 2003 Ley, et al.
    6,537,527 March, 2002 Kvalnes, et al
    6,492,326 December, 2002 Robinson, et al
    6,077,503 June, 2000 Dornoff, et al.
    5,980,904 November, 1999 Ley, et Al.
    5,932,608 August, 1999 Nguyen, et. Al.
    5,854,327 October, 1998 Neis, et al.
    5,747,006 May, 1998 Dornoff, et al.
    5,700,784 December, 1997 Shinujima, et al
    5,310,730 April, 1987 Tokugan, et al
    4,764,505 March, 1985 Tokugan, et al
    4,278,656 December, 1992 Leverett et al.
    • Foreign Patent Documents
  • 672746 September, 1995 EP.
    95/01157 January, 1995 WO.
    2577805 January, 1994 FR
    • Other References
    • Abstracts of Japan, Vol. 11, No. 297 (C448)(2744) Sep. 25, (JPA 620 896081, Apr. 24, 1987.
    • Centerchem Brochure: Alpha Arbutin, Norwalk, Conn. 2001.
    • Cosmetics & Toiletries, vol. 111, pp.43-51, Giuseppe Prota, PhD, Melatanins and Melanogenesis, 1996
    • Gattefosse Brochure: “Gatulene Whitening,” BP603-F 69804 St. Priest Cedex, France.
    • Laboratoire Serobiologiques brochure: “Dermawhite,” Nancy, France.
    • Chemical Abstracts, Vol. 87, No 5, Columbus, Ohio. Abstract 28987, 1995.
    • Youngken, H. W., Textbook of Pharmacognosy, p. 639, Blakiston, Philadelphia, 1948.
    • Rodale's Illustrated Encyclopedia of Herbs, p 170, Rodale Press, Emmaus, Pa. 1997.
    • Polyolprepolymer-2, Brochure, Barnet, Englewood Cliffs, N.J. 1999.
    • Brookosomes, Liposome Brochure, Brook's Industries Inc., South Plainfield, N.J. 2000.
    • Chemical Abstracts (121.91340) Skin Lightening Property Containing Gentistic Acid Ester. Glycosides, Shinijiana, et. al. 1994.
    FIELD OF THE INVENTION
  • The invention relates to topical cosmetic compositions, in particular, human skin lightening compositions, comprising admixtures of alpha arbutin and bearberry extract used for topical application.
    • BACKGROUND OF THE INVENTION
  • The present invention is a novel topically applied dermocosmetic composition comprising certain admixtures of the glucoside alpha arbutin and the botanical extract bearberry to be used in skin lightening.
  • Certain humans at different phases of their lifetime, and from different parts of the world, and in differing phases of their health develop excess melanin and/or colored blemishes on the skin. This excess melanin can occur on any part of the human body, but most commonly appear on the face and back of the hands. These dark spots are caused by high levels of melanin in the keratinocytes located in the top layer of the epidermis.
  • Melanocytes are located deep in the stratum granulosum, produce melanin, and through an unknown mechanism the melanin rises through about 100 cell layers to the surface where they exist as unsightly dark spots.
  • Biochemically, the process is:
      • Tyrosine amino acid (from diet) goes to Dopa; Dopa goes to Dopaquinone;
      • Dopaquinone goes to Dopachrome; Dopachrome goes to Melanin. Melanin deposits are seen as the dark spots on the surface of the human skin. They may be called “sun spots” or “age spots” or “liver spots.”
    Tyrosinase Inhibition
  • Tyrosinase is the enzyme which catalyzes the amino acid tyrosine into dopa (dihydroxyphenylamine), as well as the change from dopa into dopaquinone. Skin lightening products are designed to inhibit the action of tyrosinase.
  • Hydroquinone is the most common inhibitor of the enzyme tyrosinase. Hydroquinone is OTC Monographed (United States Food and Drug Administration 21 CFR) as a Category I skin lightener/skin bleacher/skin whitener in the concentration limits of 1.5-2.0% by weight. Used in this concentration, no clinical trials and no pre-market clearance are necessary in the USA marketplace. Used in higher concentrations than 2% by weight, hydroquinone compositions legally require a prescription in the USA marketplace. Production of hydroquinone preparations over 2% by weight requires an approved ANDA (Approved New Drug Application-21 CFR 394). However, hydroquinone is an irritant to some individuals, particularly those with light skin types, and may be cytotoxic to melanocytes. It is not legally marketed in Japan, the Union of South Africa and several other countries at present, and several other countries are considering denying legal marketing clearance because of concern about long term toxicity.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Alpha arbutin avoids the direct toxicity of hydroquinone and the indirect toxicity of beta arbutin which easily hydrolyses to hydroquinone. Alpha arbutin acts more slowly than hydroquinone, taking a slightly longer time to meet the customer's skin lightening objectives when used alone. This invention involves the use of alpha arbutin and bearberry extract in combination, This combination is synergistic in skin whitening effectiveness, as the bearberry extract serves to potentiate the alpha arbutin. Moreover, the alpha-glucosidic bond has a higher stability than the beta gluosidic bond, giving greater stability and greater effectiveness than beta arbutin.
    • Advanced Liposome Delivery System
  • This patent teaches that the use of polyolprepolymer-2 in an admixture with alpha arbutin/bearberry extract. This is in order to both extend the stability of the alpha arbutin to avoid possible deleterious effects due to oxidation related to the oxygen in the atmosphere as well as that caused by cell respiration potentiators found in epidermal respiration,
  • This invention teaches that the use of polyolprepolymer-2, when admixed with the serum comprised of alpha arbutin and octyl stearate, can be administered into the human skin using a liposome advanced delivery mechanism. Liposomes can easily be formed by those familiar in the art of liposome manufacture, using either preformed empty liposomes (Brookosomes MT) or by using ultra high pressure (20,000-40,000 PSI) in the usual microfluidizer.
    • SUMMARY OF THE INVENTION
  • In the preferred embodiment of this invention, a serum comprised of alpha arbutin 0.01-6.0% w/w (more preferably 1-4% w/w) plus bearberry extract 0.01% w/w (most preferably 1-3% w/w) is admixed with polyolprepolymer-2 0.5-10% w/w (most preferably 1-3% w/w), and this combination is further prepared into a liposome form with the use of lecithin, water and ultra high pressure microfludizer. The liposome formation is well known to those familiar in the use of the ultra high PSI providing microfluidizer.
  • This invention additionally teaches the serum-liposome admixture being further admixed into a gel or cream carrier as an advanced delivery system used in cosmetic, esthetician, spa and dermatology office settings.
  • Additionally, this stabilized alpha arbutin-polyolprepolymer 2-liposome concentrate, which has been diluted into a cosmetic carrier, is potentiated with the admixture of the proven botanical extract, bearberry extract. Moreover, additional nutrients including Vitamins A, B, C, E and Panthenol may be included in the liposome addition process.
  • Clinical testing using before and after microscopic videos establishes that this potentiation takes place in clinical, human usage.
    • Composition
  • The most preferable embodiment composition is as follows:
    Part Ingredient INCI Percentage by weight
    A Aqua (water) qs 100%
    A Methylparaben 0.23
    A Glycerin 4
    A EDTA disodium 0.12
    B Cetearyl alcohol, ceteareth 20 9
    B Propylparaben 0.12
    B Cetyl palmitate 2
    B Dimethicone 50 1
    B Steareth-20 1
    C Alpha arbutin 3
    C Octyl stearate 7
    C Polyolprepolymer-2 2
    D Lecithin, Water 1
    (Brookosomes MT)
    Lecithin, Vitamins A, C & E 1
    E Bearberry Extract 1
    (Gatulin-Gattefosse)
    • Manufacturing Procedure
  • Manufacturing procedure for the most preferred embodiment is as follows:
    • The hot part B (80 degrees C.) is mixed into the hot part A (80 degrees C.) to form the conventional emulsion core. Continue mixing and cooling.
    • Part C is prepared in a separate jacketed kettle at about 45 degrees C.
    • As part AB is mixing and cooling to about 45 degrees C., slowly add part C with mixing, then slowly add part D (all liposomes).
    • Continue to mix and cool part ABCD to about 35 degrees C. Slowly add with high agitation the Part E. Continue to mix and cool to 25 degrees C.

Claims (4)

1. A composition comprising the admixture of alpha arbutin with bearberry extract formulated into an acceptable dermatological carrier.
a. the percentage of alpha arbutin is 0.01-6.0% w/w of final composition.
b. the percentage of bearberry extract is 0.01-20% w/w of final composition.
2. The composition in claim 1 above with the alpha arbutin/bearberry extract admixture is further admixed into a polyprepolymer-2 serum.
3. The composition in claim 2 above wherein the alpha arbutin mixture is prepared partially or totally into liposome form.
4. The composition in claim 3 above wherein the final liposome carries additional nutrients such as vitamins A. C. E D and Panthenol.
US11/060,348 2005-02-18 2005-02-18 Topical cosmetic compositions comprising alpha arbutin Abandoned US20060188559A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/060,348 US20060188559A1 (en) 2005-02-18 2005-02-18 Topical cosmetic compositions comprising alpha arbutin
US11/745,632 US7431949B2 (en) 2005-02-18 2007-05-08 Topical cosmetic compositions containing alpha arbutin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/060,348 US20060188559A1 (en) 2005-02-18 2005-02-18 Topical cosmetic compositions comprising alpha arbutin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/745,632 Division US7431949B2 (en) 2005-02-18 2007-05-08 Topical cosmetic compositions containing alpha arbutin

Publications (1)

Publication Number Publication Date
US20060188559A1 true US20060188559A1 (en) 2006-08-24

Family

ID=36912998

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/060,348 Abandoned US20060188559A1 (en) 2005-02-18 2005-02-18 Topical cosmetic compositions comprising alpha arbutin
US11/745,632 Expired - Lifetime US7431949B2 (en) 2005-02-18 2007-05-08 Topical cosmetic compositions containing alpha arbutin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/745,632 Expired - Lifetime US7431949B2 (en) 2005-02-18 2007-05-08 Topical cosmetic compositions containing alpha arbutin

Country Status (1)

Country Link
US (2) US20060188559A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009256268A (en) * 2008-04-18 2009-11-05 Pias Arise Kk Retinoid stabilized composition, skin external preparation and cosmetic comprising the composition
KR101355216B1 (en) * 2012-11-19 2014-01-28 홍소영 A facial mask sheet comprising a composition comprising liposomes for accelerating percutaneous absorptionn
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
US9949913B2 (en) * 2016-03-14 2018-04-24 Jan Marini Skin Research Luminate face lotion
US20220110852A1 (en) * 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
CA2698812A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
JP6071166B2 (en) 2007-11-14 2017-02-01 オーエムピー インコーポレイテッドＯＭＰ，Ｉｎｃ． Skin treatment composition
US20100158842A1 (en) * 2008-10-09 2010-06-24 Spectrum Dynamics Llc Natural skin whitener: 4-hydroxy-oxindole-3-acetic acid
BR112021025797A2 (en) * 2019-10-16 2022-02-01 Maria Tripod Cream for acne and melasma treatment

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690948A (en) * 1997-01-10 1997-11-25 Elizabeth Arden Co., Division Of Conopco, Inc. Antisebum and antioxidant compositions containing guguliped and alcoholic fraction thereof
US5795978A (en) * 1995-11-15 1998-08-18 Henkel Kommanditgesellschaft Auf Aktien Emulsifiers
US5962015A (en) * 1997-05-02 1999-10-05 Kobo Products S.A.R.L. Stabilized liposomes
US6197775B1 (en) * 1995-06-15 2001-03-06 Mitsubishi Chemical Corporation Phosphonate nucleotide derivatives
US20030147825A1 (en) * 2001-06-08 2003-08-07 Chiarelli Joseph A. Personal care compostions containing inverse emulsion polymers
US20040028712A1 (en) * 2002-08-12 2004-02-12 Shepherd Walter B Composition containing leukocyte extract for the whitening or lightening of skin
US20040208902A1 (en) * 2003-04-18 2004-10-21 Gupta Shyam K. Controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compositions
US20050019282A1 (en) * 2003-07-22 2005-01-27 Rendon Marta I. Method and topical composition for the treatment of hyperpigmented skin
US20050048008A1 (en) * 2003-08-29 2005-03-03 Bioderm Research Antiaging Cosmetic Delivery Systems

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS567710A (en) * 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
JPH0832621B2 (en) * 1985-02-28 1996-03-29 株式会社資生堂 Topical skin
US5234682A (en) * 1990-06-21 1993-08-10 Revlon Consumer Products Corporation Cosmetic compositions
US5389363A (en) * 1993-04-23 1995-02-14 Revlon Consumer Products Corporation Cosmetic compositions for lengthening, coloring and curling eyelashes
US5700784A (en) * 1993-10-26 1997-12-23 Shiseido Co., Ltd. External preparation for skin
US6068834A (en) * 1994-03-04 2000-05-30 The Procter & Gamble Company Skin lightening compositions
EP0672746B1 (en) 1994-03-18 2002-05-29 Givaudan SA Oxime ethers and perfume and flavouring compositions containing them
FR2751535B1 (en) * 1996-07-25 1998-11-27 Oreal USE OF MELATONIN DERIVATIVES FOR DEPIGMENTATION OF THE SKIN AND COMPOSITIONS COMPRISING THE SAME
US6068847A (en) * 1996-10-03 2000-05-30 Johnson & Johnson Consumer Products, Inc. Cosmetic compositions
US5747006A (en) * 1997-05-14 1998-05-05 Amway Corporation Skin whitener composition containing acerola cherry fermentate
US5854327A (en) * 1997-06-27 1998-12-29 Bridgestone/Firestone, Inc. Mineral-filled roofing membrane compositions and uses therefor
US6077503A (en) * 1997-07-30 2000-06-20 Amway Corporation Skin whitener composition containing mercaptodextran
US5824327A (en) 1998-04-06 1998-10-20 Whittemore; Jerry Kojic dipalmitate skin whitening comestic composition
US5980904A (en) * 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
US6492326B1 (en) * 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
AU4267500A (en) 1999-07-08 2001-01-11 Haarmann & Reimer Gmbh Topical cosmetic compositions comprising benzaldoximes
WO2001056881A1 (en) * 2000-02-03 2001-08-09 Mobile Communications Holdings, Inc. Virtually geostationary satellite array
US6790452B2 (en) * 2002-06-25 2004-09-14 Miyoshi Kasei, Inc. Pigment dispersions and cosmetic products containing the same
JP4478021B2 (en) * 2002-08-30 2010-06-09 チバ ホールディング インコーポレーテッド Colored luster pigments with at least one coating of SiOx where X = 0.03 to 0.95 for use in cosmetic and personal care formulations
KR100778992B1 (en) * 2004-01-07 2007-11-28 이엘씨 매니지먼트 엘엘씨 Cosmetic Composition and Method for Retarding hair growth

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197775B1 (en) * 1995-06-15 2001-03-06 Mitsubishi Chemical Corporation Phosphonate nucleotide derivatives
US5795978A (en) * 1995-11-15 1998-08-18 Henkel Kommanditgesellschaft Auf Aktien Emulsifiers
US5690948A (en) * 1997-01-10 1997-11-25 Elizabeth Arden Co., Division Of Conopco, Inc. Antisebum and antioxidant compositions containing guguliped and alcoholic fraction thereof
US5962015A (en) * 1997-05-02 1999-10-05 Kobo Products S.A.R.L. Stabilized liposomes
US20030147825A1 (en) * 2001-06-08 2003-08-07 Chiarelli Joseph A. Personal care compostions containing inverse emulsion polymers
US20040028712A1 (en) * 2002-08-12 2004-02-12 Shepherd Walter B Composition containing leukocyte extract for the whitening or lightening of skin
US20040208902A1 (en) * 2003-04-18 2004-10-21 Gupta Shyam K. Controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compositions
US20050019282A1 (en) * 2003-07-22 2005-01-27 Rendon Marta I. Method and topical composition for the treatment of hyperpigmented skin
US20050048008A1 (en) * 2003-08-29 2005-03-03 Bioderm Research Antiaging Cosmetic Delivery Systems

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009256268A (en) * 2008-04-18 2009-11-05 Pias Arise Kk Retinoid stabilized composition, skin external preparation and cosmetic comprising the composition
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
KR101355216B1 (en) * 2012-11-19 2014-01-28 홍소영 A facial mask sheet comprising a composition comprising liposomes for accelerating percutaneous absorptionn
US9949913B2 (en) * 2016-03-14 2018-04-24 Jan Marini Skin Research Luminate face lotion
US20220110852A1 (en) * 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers
CN114344186A (en) * 2020-10-14 2022-04-15 C·扎维拉 Pigment Stabilizer

Also Published As

Publication number Publication date
US7431949B2 (en) 2008-10-07
US20070207110A1 (en) 2007-09-06

Similar Documents

Publication Publication Date Title
US7431949B2 (en) Topical cosmetic compositions containing alpha arbutin
KR100928211B1 (en) Compositions for the treatment of sun damage and compositions for reducing acne lesions
CN109998938B (en) Polypeptide composition for whitening, brightening and lightening spots
EP1879549B1 (en) Personal care compositions comprising a dipeptide
EP3957296B1 (en) Low ph skin care composition and methods of using the same
FR2680466A1 (en) PREPARATION FOR WHITENING THE SKIN.
US6436378B1 (en) Composition
TW200526263A (en) Holistic composition and method for reducing skin pigmentation
TW201818919A (en) Compositions of LITHOSPERMUM ERYTHRORHIZON (GROMWELL ROOT) and methods of making and using the compositions
AU2002360571B2 (en) Methods for improving the aesthetic appearance of skin
ES3030988T3 (en) Cosmetic, nutraceutical or dermatological use of a lactobacillus crispatus strain and/or of a composition comprising same
US20150132236A1 (en) Compositions containing low levels of colorant to enhance skin appearance
US10537507B2 (en) All-in-one skin brightening formulations specifically for pregnant subjects
US12171852B1 (en) Composition and methods for regulating melanogenesis
CN1121850C (en) Use of unfermented honey as decolouring agent
US12036302B2 (en) Method of treating oxidative stress in skin and compositions therefor
US20250295562A1 (en) Formulation for treatment of melasma, hyperpigmentation, and dark spots
CN121081310A (en) Whitening and freckle-removing composition and application thereof
AU2009212783A1 (en) Soy depigmenting and skin care compositions
WO2010049463A1 (en) Depigmenting topical compositions and their uses
Olavarria Niacinamide Deep Dive: Why It’s in Every Good Skincare Routine
HK1231426B (en) Skin-brightening cosmetic composition
KR20060048931A (en) Compositions and Methods for Treating Skin Diseases

Legal Events

Date Code Title Description
AS Assignment

Owner name: E.T. BROWN DRUG CO., INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NEIS, ARNOLD;NEIS, ROBERT;WHITTEMORE, JERRY;REEL/FRAME:016670/0334;SIGNING DATES FROM 20050526 TO 20050601

AS Assignment

Owner name: E.T. BROWNE DRUG CO., INC., NEW JERSEY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 016670 FRAME 0334;ASSIGNORS:NEIS, ARNOLD;NEIS, ROBERT;WHITTEMORE, JERRY;REEL/FRAME:017116/0975;SIGNING DATES FROM 20050526 TO 20050601

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION